Curie Therapeutics unveils $75M to widen scope of radiopharmaceuticals for cancer

Radiopharmaceuticals deploy radiation to damage cancer DNA, but Curie Therapeutics sees these therapies opening the door to a wider range of ways to kill tumors. The startup has raised $75 million in Series A financing to advance its research.